Formulation and Development of Transdermal Patches of Piroxicam

Agrahari Saurabh¹, Sharma Atul¹, Kumar Sachin¹, Sharma Amit², Sagar Manoj Kumar³.

¹ Department of Pharmaceutics NKBR College of Pharmacy & Research Centre Meerut U.P.  
² Dept. of Pharmacy Manav Bharti University, Village-Laddo, Sultanpur, Kumarhatti, District Solan, Himachal Pradesh. India  
³ Department of Pharmaceutical chemistry NKBR College of Pharmacy & Research Centre Meerut U.P.

ABSTRACT

The aim of the given study was to formation as well as development of patches of piroxicam. Piroxicam basically a steroidal anti-inflammatory drug. Less dosage result in the longer duration of action which make these patches a remarkable in curing the infection for the increase of transdermal properties of the patches various batches were prepared using hydroxyl propyl methyl cellulose, ethyl cellulose and poly vinyl pyrrolidone for best result various parameters are considered like thickness, weight are considered during various test in different batches and the last are i.e. the 6th batch comes good result batch 6th show best evaluation parameter whereas batch 7th show a 95% release of drug those parameters including moisture content and above mention were tested and were evaluated for best possible result.

Key words: Hydroxyl propyl methyl cellulose, ethyl cellulose, poly vinyl pyrrolidone, Piroxicam.

ARTICLE INFO: Received 13 April 2019; Review Completed 25 May 2019; Accepted 31 May 2019; Available online 15 June 2019

Cite this article as: Agrahari Saurabh, Sharma Atul, Kumar Sachin, Sharma Amit, Sagar Manoj Kumar, Formulation and Development of Transdermal Patches of Piroxicam, Asian Journal of Pharmaceutical Research and Development. 2019; 7(3): 119-128.

DOI: http://dx.doi.org/10.22270/ajprd.v7i3.511

*Address for Correspondence:
Amit Sharma, Asst. Professor Dept. of Pharmacy Manav Bharti University, Village-Laddo, Sultanpur, Kumarhatti, District Solan, Himachal Pradesh. India

INTRODUCTION

Transdermal drug delivery system is self-contained, discrete dosage form in which drug stick to the body surface and delivers the drug, across the skin at controlled rate in to the blood stream. TDDS has been a great field of interest in recent times. Many drugs which can be injected directly into the blood stream via skin have been formulated by TDDS. Transdermal drug delivery system (TDDS) provides a means to sustain drug release as well as reduce the intensity of action and thus reduce the side effects associated with its oral therapy.

Advantages

- An equivalent therapeutic effect can be elicited via transdermal drug input with a lower daily dose of the drug than is necessary, e.g. the drug is given orally.

Disadvantages

- Many drugs especially drugs with hydrophilic structures permeate the skin too slowly to be of therapeutic benefit.
- The barrier function of the skin changes from one site to another on the same person, from person to person and also with age.

Drug delivery routes across human skin

Drug molecules can penetrate by three pathways:

- Sweat ducts
Factors affecting transdermal drug delivery:-

(A) Physicochemical properties of permeant

Partition coefficient

For molecules with intermediate partition coefficient (log K 1 to 3) and for highly lipophilic molecules (log K>3), the intercellular route will be almost the pathway used to traverse the stratum corneum. However, for these molecules a further consideration is the ability to partition out of the stratum corneum into the aqueous viable epidermal tissues. For more hydrophilic molecules (log K<1), the transcellular route probably predominates.

Molecular size

A second major factor in determining the flux of a material through human skin is the size of the molecule. However, for simplicity the molecular weight is generally taken as an approximation of molecular size. It has been suggested that an inverse relationship existed between transdermal flux and molecular weight of the molecule.

Solubility/melting point

It is well known that most organic materials with high melting points have relatively low aqueous solubility at normal temperature and pressure. The lipophilic molecules tend to permeate through the skin faster than more hydrophilic molecules. However, while lipophilicity is a desired property of transdermal candidates, it is also necessary for the molecule to exhibit some aqueous solubility since topical medicaments are generally applied from an aqueous formulation.

B) Physicochemical properties of the drug delivery system

Release characteristics

Solubility of the drug in the vehicle determines the release rate. The mechanism of drug release depends on the following factors:

- Whether the drug molecules are dissolved or suspended in the delivery systems.
- The interfacial partition coefficient of the drug from the delivery system to the skin tissue.
- pH of the vehicle.

C) Physiological factors

1. Skin barrier properties in the neonate and young infant

The skin of newborns is known to be relatively susceptible to irritants, other variables related to stratum corneum function such as pH and stratum corneum hydration may enhance the irritant potential to newborn skin.

2. Skin barrier properties in aged skin

There are changes in the physiology of aged skin (>65 years). The corneocytes are shown to increase in surface area which may have implications for stratum corneum function due to the resulting decreased volume of intercorneocyte space per unit volume of stratum corneum.

3. Race

Racial differences between black and white skins have been shown in some anatomical and physiological functions of the skin although data is relatively sparse. In black skin, increased intracellular cohesion, higher lipid content and higher electrical skin resistance levels compared to whites have been demonstrated.

5. Skin temperature

The human body maintains a temperature gradient across the skin from around 37 ºC to around 32 ºC at the outer surface.

COMPONENTS OF TRANSDERMAL PATCHES:

(I) Polymer Matrix

The polymer controls the release of the drug from the device. The following criteria should be satisfied for a polymer to be used in transdermal patches.

- The polymer should be stable.
- The polymer should be nontoxic

Types of polymer:

(a) Natural polymers
(b) Synthetic Elastomers
(c) Synthetic polymers

(II) Drug

Drug solution in direct contact with release liner.

Physiochemical properties

1) The drug should have a molecular weight less than 1000 Daltons.
2) The drug should have affinity for both lipophilic and hydrophilic phases.

Biological properties

- The drug should be potent with a daily dose of the order of a few mg/day.
- The half life (t½) of the drug should be short.
- The drug must not produce allergic response.

(III) Permeation Enhancer

The flux J. of drug across the skin can be write As

\[ J = D \frac{dc}{dx} \]

where J = The Flux, D = diffusion coefficient, C = Concentration of the diffusing spectes, X = Spatial coordinate

TYPES OF TRANSDERMAL PATCHES

Single-layer Drug-in-Adhesive

The adhesive layer of this system also contains the drug. In this type of patch the adhesive layer not only serves to adhere the various layers together, along with the entire system to the skin, but is also responsible for the releasing of the drug.
Reservoir

Unlike the Single-layer and Multi-layer Drug-in adhesive systems the reservoir transdermal system has a separate drug layer.

Figure 1: Single layer transdermal patch

Figure 2: Reservoir transdermal patch

METHODS OF PREPARATION OF TRANSDERMAL PATCHES

Asymmetric TPX membrane method

A prototype patch can be fabricated for this a heat sealable polyester film (type 1009, 3m) with a concave of 1cm diameter will be used as the backing membrane. Drug sample is dispensed into the concave membrane, covered by a TPX (poly (4-methyl-1-pentene)) asymmetric membrane, and sealed by an adhesive.

Circular teflonmould method

Solutions containing polymers in various ratios are used in an organic solvent. Calculated amount of drug is dissolved in half the quantity of same organic solvent. Enhancers in different concentrations are dissolved in the other half of the organic solvent and then added. Di-N-butylphthalate is added as a plasticizer into drug polymer solution. The total contents are to be stirred for 12 hrs and then poured into a circular teflonmould. The moulds are to be placed on a leveled surface Associate in Nursing lined with foil and also the ends blanked off to provide an even dispersion and poured in to a leveled mercury surface, lined with inverted funnel to manage solvent evaporation.

Mercury substrate method

In this method drug is dissolved in polymer solution along with plasticizer. The higher than resolution is to be stirred for 10-12 hour to provide an even dispersion and poured in to a leveled mercury substrate, lined with inverted funnel to manage solvent evaporation.

By using “IPM membranes” method

In this methodology drug is distributed in a very mixture of water and propanediol containing carbomer 940 compound and stirred for twelve hrs in magnetic stirrer. The dispersion is to be neutral and created viscous by the addition of triethanolamine. Buffer pH scale seven.4 will be employed in order to get resolution gel, if the drug solubility in solution is extremely poor. The shaped gel are going to be incorporated within the IPM membrane.

By using “EVAC membranes” method

In order to prepare the target transdermal therapeutic system, 1% carbopol reservoir gel, polyethylene (PE), ethylene vinyl acetate copolymer (EVAC) membranes can be used as rate control membranes. If the drug is not soluble in water, propylene glycol is used for the preparation of gel. Drug is dissolved in propylene glycol, carbopol resin will be added to the above solution and neutralized by using 5% w/w sodium hydroxide solution. The drug (in gel form) is placed on a sheet of backing layer covering the specified area. A rate controlling membrane will be placed over the gel and the edges will be sealed by heat to obtain a leak proof device.

Aluminium backed adhesive film method

Transdermal drug delivery system may produce unstable matrices if the loading dose is greater than 10 mg. Aluminium backed adhesive film method is a suitable one. For preparation of same, chloroform is choice of solvent, because most of the drugs as well as adhesive are soluble in chloroform. The drug is dissolved in chloroform and material is going to be additional to the drug answer and dissolved. A custommade aluminum former is lined with foil and also the ends blanked off with tight cork blocks.

Preparation of TDDS by using Proliposomes

The proliposomes area unit ready by carrier technique exploitation film deposition technique. From the soonerreference drug and emulsifier within the quantitative relation of zero.1:2.0 are often used as AN optimized one. The proliposomes area unit ready by taking 5mg of water pill powder during a one hundred cubic centimeter spherical bottom flask that is unbroken at 60-70°C temperature and also the flask is revolved at 80-90 revolutions per minute and dried the water pill at vacuum for half-hour. Once drying, the temperature of the water bat is adjusted to 20-30°C. Drug and lecithin are dissolved during a appropriate organic solvent mixture, a 0.5ml aliquot of the organic answer is introduced into the spherical flat-bottom flask at 37°C, once complete drying second aliquots (0.5ml) of the answer is to be supplementary. Once the last loading, the flask containing proliposomes area unit connected during a lyophilizer and afterwards drug loaded water pill powders (proliposomes) area unit placed during a desiccator over night then sieved through one hundred mesh. The collected powder is transferred into a glass bottle and keep at the freeze temperature till characterization.

By using free film method

Free film of cellulose acetate is prepared by casting on mercury surface. A polymer solution 2% w/w is to be prepared by using chloroform. Plasticizers are to be
incorporated at a concentration of 40% w/w of polymer weight. Five ml of polymer solution was poured in a glass ring which is placed over the mercury surface in a glass petri dish. The rate of evaporation of the solvent is controlled by placing an inverted funnel over the petri dish. The film formation is noted by observing the mercury surface after complete evaporation of the solvent. The dry film will be separated out and stored between the sheets of wax paper in a desiccator until use. Free films of different thickness can be prepared by changing the volume of the polymer solution.

CHARACTERIZATION OF TRANSDERMAL PATCHES

Thickness of the patch

The thickness of the drug loaded patch is measured at different points by using a digital micrometer and the average thickness and standard deviation is determined to ensure the thickness of the prepared patch.

Weight uniformity

The prepared patches are dried at 60°C for 4hrs before testing. A specified area of patch is to be cut in different parts of the patch and weigh in digital balance. The average weight and standard deviation values are to be calculated from the individual weights.

Percentage Moisture content

The prepared films are to be weighed individually and to be kept in a desiccators containing fused calcium chloride at room temperature for 24 hrs. After 24 hrs the films are to be reweighed and determine the percentage moisture content from the below mentioned formula

\[
\% \; \text{Moisture content} = \frac{\text{Initial weight} - \text{Final weight}}{\text{Initial weight}} \times 100
\]

Content uniformity test

10 patches are selected and content is determined for individual patches. If 9 out of 10 patches have content between 85% to 115% of the specified value and one has content not less than 75% to 125% of the specified value, then transdermal patches pass the test of content uniformity. But if 3 patches have content in the range of 75% to 125%, then additional 20 patches are tested for drug content. If these 20 patches have range from 85% to 115%, then the transdermal patches pass the test.

MATERIAL AND METHODS:

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Ingredient</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Drug (Piroxicam)</td>
<td>Idma laboratories Lid Haryana</td>
</tr>
<tr>
<td>2</td>
<td>PVP</td>
<td>LOBA chem.</td>
</tr>
<tr>
<td>3</td>
<td>PEG-400</td>
<td>S.D. Fine chemical Ltd.</td>
</tr>
<tr>
<td>4</td>
<td>HPMC</td>
<td>LOBA chem.</td>
</tr>
<tr>
<td>5</td>
<td>EC</td>
<td>LOBA chem.</td>
</tr>
<tr>
<td>6</td>
<td>Ethanol</td>
<td>LOBA chem.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Equipment</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Glass wares</td>
<td>Borocil</td>
</tr>
<tr>
<td>2</td>
<td>Melting point apparatus</td>
<td>Almicro</td>
</tr>
<tr>
<td>3</td>
<td>UV Spectrophotometer</td>
<td>Lab India</td>
</tr>
<tr>
<td>4</td>
<td>IR Spectrophotometer</td>
<td>FOPh. J.N.U.</td>
</tr>
</tbody>
</table>

Preformulation studies

Preformulation testing is the first step in the rational development of dosage forms of a drug. It can be defined as an investigation of physical and chemical properties of drug substance, alone and when in combined with excipients. The overall objective of the preformulation testing is to generate information useful to the formulator in developing stable and bioavailability dosage forms which can be mass produced.

The goals of preformulation studies are:

- To establish the necessary physicochemical characteristics of a new drug substance.
- To determine its kinetic release rate profile.
- To establish it’s compatibility with different excipients.

Characterization of Piroxicam

Melting point determination

The melting point of piroxicam was determined by using melting point apparatus with the help of fine capillary.

Spectroscopic studies

FTIR spectrum interpretation

The infrared spectrum of the pure piroxicam sample was recorded and the spectral analysis was done. The dry sample of drug was directly placed after mixing and triturating with dry potassium bromide.

UV Analysis

A standard solution (10µg/ml) of Piroxicam was prepared in 0.1M NaOH and scanned by UV-VIS spectrophotometer (Lab India) between 200 to 400nm. The λ max was found to be 336 nm.

Construction of calibration curve of piroxicam

Accurately weighed 10 mg of drug was dissolved in 100 ml of 0.1M NaOH to give a solution of 100 µg/ml concentration. From this solution 1ml was taken and diluted to 10 ml using 0.1M NaOH to get a stock solution of 10µg/ml. From this stock solution various aliquots ranging from 1-10 µg/ml were prepared. The absorbance of these solutions was measured spectrophotometrically at 336 nm against reference blank.

Determination of solubility of Piroxicam

Piroxicam solubility was determined in distilled water and phosphate buffer. The procedure can be detailed as follows:- in small glass vials solvent was taken and solubility was determined by making saturated solution of drug the drug was gradually added till the solutions turned cloudy indicating the presence of undissolved drug the solutions were kept at rest for 24hrs to assist the attainment of equilibrium with undissolved drug particles the supernatants were decanted and filtered through filter paper the filtrates were suitably diluted and the absorbance were measured at 336 nm.

Partition coefficient

The partition coefficient of the drug was determined by shaking equal volumes of oil and aqueous phases in a separating funnel drug solution of 1 mg/ml was prepared in octanol. 50 ml of this solution was taken in a separating funnel and shaken with an equal volume of distilled water for 10 minutes and allowed to stand for 1hour. Then the oil
Formulation of Transdermal Patches

Transdermal patches of piroxicam were prepared by solvent casting technique. Ethanolic solution of polymer and drug along with polyethylene glycol (plasticizer) was prepared. The homogenous mixture was poured into plastic mould. The solvent was allowed to evaporate at controlled rate by placing an inverted funnel over the plastic mould. The control of evaporation is necessary for uniform drying of films. The drying was carried out at room temperature for duration of 24 hours. After 24 hours the dry films was removed from plastic mould and stored in desiccators until used.

<table>
<thead>
<tr>
<th>Formulation Code</th>
<th>Piroxicam (mg)</th>
<th>Polymer Combination</th>
<th>Polymer Ratio</th>
<th>Permeation enhancer (Oleic acid)</th>
<th>Plasticizer (PEG)</th>
<th>Solvent</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>100</td>
<td>EC:PVP</td>
<td>1.0:0.5</td>
<td>0.5%</td>
<td>0.5%</td>
<td>Ethanol</td>
</tr>
<tr>
<td>F2</td>
<td>100</td>
<td>EC: PVP</td>
<td>1.0:0.5</td>
<td>0.5%</td>
<td>-</td>
<td>Ethanol</td>
</tr>
<tr>
<td>F3</td>
<td>100</td>
<td>HPMC: PVP</td>
<td>1.0:1.0</td>
<td>0.5%</td>
<td>0.5%</td>
<td>Ethanol</td>
</tr>
<tr>
<td>F4</td>
<td>100</td>
<td>HPMC: EC: PVP</td>
<td>0.5:1.0</td>
<td>0.5%</td>
<td>-</td>
<td>Ethanol</td>
</tr>
<tr>
<td>F5</td>
<td>100</td>
<td>HPMC: PVP</td>
<td>1.0:1.0</td>
<td>0.5%</td>
<td>-</td>
<td>Ethanol</td>
</tr>
<tr>
<td>F6</td>
<td>100</td>
<td>HPMC: PVP</td>
<td>1.0:1.0</td>
<td>0.5%</td>
<td>1.0%</td>
<td>Ethanol</td>
</tr>
<tr>
<td>F7</td>
<td>100</td>
<td>HPMC: EC: PVP</td>
<td>1.0:1.1</td>
<td>0.5%</td>
<td>-</td>
<td>Ethanol</td>
</tr>
<tr>
<td>F8</td>
<td>100</td>
<td>HPMC: EC: PVP</td>
<td>0.5:0.5:1.0</td>
<td>0.5%</td>
<td>1.0%</td>
<td>Ethanol</td>
</tr>
</tbody>
</table>

Evaluation of Transdermal Patches

Physical appearance

The prepared patches were physically examined for colour, clarity and surface texture.

Thickness of the patch

The thickness of the drug loaded patch was measured in different points by using a digital micrometer and determines the average thickness and standard deviation for the same to ensure the thickness of the prepared patch.

Weight uniformity

The prepared patches were weighed individually and to be kept in a desiccators containing fused calcium chloride at room temperature for 24 hrs. After 24hrs the films are to be reweighed and determine the percentage moisture content from the below mentioned formula.

\[
\text{Percentage Moisture content} = \frac{\text{Initial weight} - \text{Final weight}}{\text{Final weight}} \times 100
\]

Result:-

Formulations of Piroxicam transdermal patches were formulated using different polymer ratios. The prepared formulations are shown in figure. The formulations are subjected to evaluation parameters like thickness, drug content, folding endurance, tensile strength, percentage elongation, percentage moisture absorption, FTIR studies.
Figure 3: FTIR Spectroscopy of Piroxicam

The FTIR spectra of piroxicam is shown in fig. 5.1., the main characteristic peak of piroxicam was the secondary amine N-H stretching which appeared at 3338 cm\(^{-1}\). It has been reported that piroxicam has two inter convertible crystalline forms, namely the needle and cubic forms. The IR absorption peaks at 1634 cm\(^{-1}\) and 1629 cm\(^{-1}\) are assigned to the stretching of the amide carbonyl groups of the needle form and the cubic form respectively, the peak at 1529 cm\(^{-1}\) is due to the stretching of the second amide band for both crystalline forms of piroxicam. In the present study, the peak at 1629.55 cm\(^{-1}\) was found in the IR spectrum of piroxicam, suggesting that the cubic form of piroxicam was used.

Figure 4: FTIR of Piroxicam + Hydroxy propyl methyl cellulose (HPMC)

The PIR (Piroxicam Infrared Spectra) also exhibited other characteristic peaks like, C=N stretching vibration of pyridyl nitrogen assigned at 1577.49 cm\(^{-1}\), C=C stretching of pyridine ring at 1531.2 cm\(^{-1}\), C=C stretching of aromatic ring at 1434.78 cm\(^{-1}\), C-N stretching at 1349.79 cm\(^{-1}\), C-O stretching at 1214.93 cm\(^{-1}\), S(=O)\(_2\) stretching at 1149.37 cm\(^{-1}\), -SO\(_2\)-N stretching at 1064 cm\(^{-1}\), aromatic CH bending at 875.52 cm\(^{-1}\), ortho-disubstituted phenyl at 773.89 cm\(^{-1}\) and C-S stretching at 690.39 cm\(^{-1}\) [49,50]. HPMC fig. 5.2 showed an ester C=O stretching peak around 1724 cm\(^{-1}\). The pattern of the selected transdermal formula showed band at 3336.88 cm\(^{-1}\) which was related to the N-H stretching and all the original peaks of the pure drug remained without changing, the existence of 1629 cm\(^{-1}\) indicates that the piroxicam was fixed in the cubic polymorphic form and no interaction with accidents occurred. Specific changes in IR spectra are not very clear. This could be due to variations in the resonance structure, rotation of a part of a molecule or certain bond, so it was can concluded that there is no interaction between piroxicam: HPMC:PVP:EC after evaporation of the solvent.

Figure 5: FTIR of piroxicam + Poly vinyl pyrrolidone (PVP)

Figure 6: FTIR of piroxicam + Poly vinyl pyrrolidone + Ethyl cellulose + Hydroxy propyl methyl cellulose.

Determination of \(\lambda_{\text{max}}\)

A standard solution (10µg/ml) of Piroxicam was prepared in 0.1M NaOH and scanned by UV-VIS spectrophotometer (Lab India) between 200 to 400nm. The \(\lambda_{\text{max}}\) was found to be 336 nm the spectrum.

Figure 7: UV spectrum of piroxicam

Calibration curve of Piroxicam

Accurately weighed 10 mg of drug was dissolved in 100 ml of 0.1M NaOH to give a solution of 100 µg/ml concentration. From this solution 1ml was taken and diluted to 10 ml using 0.1M NaOH to get a stock solution of 10µg/ml. From this stock solution various aliquots ranging from 1-10 µg/ml were prepared. The absorbance of these solutions was measured spectrophotometrically at 336 nm against reference blank. Piroxicam was found to obey Beer-Lambert’s law in the concentration range of 0-
14µg/ml with regression coefficient ($r^2$) value 0.994 the regression equation was calculated as $y = 0.009x - 0.004$ in 0.1M NaOH.

Table 4: Calibration curve of piroxicam in pH 7.4 phosphate buffer solution

<table>
<thead>
<tr>
<th>Concentration µg/ml</th>
<th>Absorbance at 336 nm</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.000</td>
</tr>
<tr>
<td>2</td>
<td>0.172</td>
</tr>
<tr>
<td>4</td>
<td>0.328</td>
</tr>
<tr>
<td>6</td>
<td>0.509</td>
</tr>
<tr>
<td>8</td>
<td>0.660</td>
</tr>
<tr>
<td>10</td>
<td>0.818</td>
</tr>
<tr>
<td>12</td>
<td>0.976</td>
</tr>
<tr>
<td>14</td>
<td>1.120</td>
</tr>
<tr>
<td>16</td>
<td>1.126</td>
</tr>
</tbody>
</table>

Figure 8: Calibration curve of Piroxicam in pH 7.4 buffer

Solubility studies
The solubility of different formulation in water and pH 7.4 phosphate buffer was determined. Excess quantities of prepared formulation were taken into screw-capped 50 ml glass vials filled with water and pH 7.4 phosphate buffer. The vials were shaken for 24 hours on mechanical shaker. The solution was filtered through Whatmann filter paper and the drug concentration was determined spectrophotometrically.

Table 5: Solubility data for piroxicam

<table>
<thead>
<tr>
<th>Solubility medium</th>
<th>Solubility (mg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water</td>
<td>0.143 mg/ml</td>
</tr>
<tr>
<td>PEG 600</td>
<td>9.438 mg/ml</td>
</tr>
<tr>
<td>Propylene Glycol</td>
<td>2.562 mg/ml</td>
</tr>
</tbody>
</table>

Physical evaluation

Thickmess
The thickness of the Patches varied from 0.42 ± 0.31 to 0.45 ± 0.86 mm. The values obtained for all the formulations.

Moisture absorption
The % moisture absorption was in the range of 2.46 ± 0.29 to 4.73 ± 0.22 and 4.14 ± 0.68 to 5.59 ± 0.17 at 75 % RH and 85 % RH, respectively.

Moisture content
The moisture content of the formulation ranges from 2.13 ± 0.39 to 3.42 ± 0.21. The value for the moisture content.

Folding Endurance
The folding endurance was found to be in the range of >100. This data revealed that the patches had good mechanical strength along with flexibility the values for all the formulation is tabulated.

Drug content
The drug content was in the range of 94.57 ± 0.36 to 97.58 ± 0.85.

Table 6: Results of various evaluation parameters of the prepared transdermal patches

<table>
<thead>
<tr>
<th>Formulation code</th>
<th>Weight variation (mg)</th>
<th>Thickness (µm)</th>
<th>Drug Content (%)</th>
<th>Flatness %</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>160.64 ± 0.92</td>
<td>0.43± 0.22</td>
<td>94.57 ± 0.36</td>
<td>100</td>
</tr>
<tr>
<td>F2</td>
<td>161.03 ± 0.83</td>
<td>0.42± 0.31</td>
<td>95.11 ± 0.28</td>
<td>100</td>
</tr>
<tr>
<td>F3</td>
<td>160.33 ± 0.47</td>
<td>0.44± 0.95</td>
<td>95.24 ± 0.38</td>
<td>100</td>
</tr>
<tr>
<td>F4</td>
<td>160.66 ± 0.94</td>
<td>0.45± 0.33</td>
<td>96.35 ± 0.28</td>
<td>100</td>
</tr>
<tr>
<td>F5</td>
<td>160.33 ± 0.48</td>
<td>0.43± 0.88</td>
<td>95.64 ± 0.45</td>
<td>100</td>
</tr>
<tr>
<td>F6</td>
<td>160.66 ± 0.96</td>
<td>0.42± 0.94</td>
<td>97.58 ± 0.85</td>
<td>100</td>
</tr>
<tr>
<td>F7</td>
<td>161.33 ± 0.95</td>
<td>0.45± 0.86</td>
<td>96.45 ± 0.27</td>
<td>100</td>
</tr>
<tr>
<td>F8</td>
<td>160.66 ± 0.93</td>
<td>0.45± 0.75</td>
<td>95.63 ± 0.76</td>
<td>100</td>
</tr>
</tbody>
</table>
Table 7: Results of various evaluation parameters of the prepared transdermal patches.

<table>
<thead>
<tr>
<th>Formulation code</th>
<th>Tensile strength (N/mm²)</th>
<th>Folding endurance</th>
<th>MVTR (%)</th>
<th>Moisture content (%)</th>
<th>Moisture Absorption (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>75% RH</td>
<td>85% RH</td>
<td></td>
</tr>
<tr>
<td>F1</td>
<td>5.12±0.580</td>
<td>138±1.05</td>
<td>2.35±0.42</td>
<td>3.42±0.21</td>
<td>2.46±0.29</td>
</tr>
<tr>
<td>F2</td>
<td>5.48±0.255</td>
<td>135±1.49</td>
<td>1.45±0.32</td>
<td>2.37±0.35</td>
<td>3.32±0.71</td>
</tr>
<tr>
<td>F3</td>
<td>5.50±0.200</td>
<td>128±1.09</td>
<td>1.21±0.19</td>
<td>2.51±0.29</td>
<td>3.79±0.23</td>
</tr>
<tr>
<td>F4</td>
<td>5.56±0.070</td>
<td>122±1.69</td>
<td>1.48±0.32</td>
<td>2.13±0.39</td>
<td>4.03±0.45</td>
</tr>
<tr>
<td>F5</td>
<td>5.57±0.265</td>
<td>119±1.26</td>
<td>2.34±0.44</td>
<td>2.47±0.51</td>
<td>4.23±0.13</td>
</tr>
<tr>
<td>F6</td>
<td>5.44±0.202</td>
<td>118±1.05</td>
<td>2.12±0.76</td>
<td>2.41±0.28</td>
<td>3.08±0.32</td>
</tr>
<tr>
<td>F7</td>
<td>5.48±0.133</td>
<td>112±1.05</td>
<td>2.63±0.23</td>
<td>3.36±0.42</td>
<td>4.55±0.17</td>
</tr>
<tr>
<td>F8</td>
<td>5.42±0.212</td>
<td>109±1.49</td>
<td>2.38±0.62</td>
<td>2.45±0.33</td>
<td>4.73±0.22</td>
</tr>
</tbody>
</table>

In-Vitro Studies

Table 8: The In vitro studies data of formulation of piroxicam.

<table>
<thead>
<tr>
<th>Formulation code</th>
<th>Time (min)</th>
<th>15</th>
<th>30</th>
<th>45</th>
<th>60</th>
<th>120</th>
<th>180</th>
<th>240</th>
<th>360</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>15</td>
<td>30</td>
<td>45</td>
<td>60</td>
<td>120</td>
<td>180</td>
<td>240</td>
<td>360</td>
</tr>
<tr>
<td>F1</td>
<td></td>
<td>3.85±2.57</td>
<td>7.18±2.52</td>
<td>10.73±2.0</td>
<td>15.35±2.4</td>
<td>19.23±2.0</td>
<td>23.60±2.58</td>
<td>27.99±2.66</td>
<td>36.31±2.13</td>
</tr>
<tr>
<td>F2</td>
<td></td>
<td>11.58±4.39</td>
<td>17.50±3.5</td>
<td>27.74±5.7</td>
<td>34.78±4.5</td>
<td>40.30±3.2</td>
<td>46.00±3.96</td>
<td>54.16±4.1</td>
<td>36.35±3.33</td>
</tr>
<tr>
<td>F3</td>
<td></td>
<td>1.27±3.01</td>
<td>3.75±3.63</td>
<td>6.30±3.48</td>
<td>8.30±4.8</td>
<td>11.08±4.2</td>
<td>14.18±3.87</td>
<td>21.86±2.58</td>
<td>36.31±0.88</td>
</tr>
<tr>
<td>F4</td>
<td></td>
<td>6.41±1.39</td>
<td>12.81±1.2</td>
<td>21.66±2.1</td>
<td>31.51±1.7</td>
<td>38.26±1.8</td>
<td>47.60±1.96</td>
<td>56.30±2.42</td>
<td>36.31±1.57</td>
</tr>
<tr>
<td>F5</td>
<td></td>
<td>3.22±1.36</td>
<td>4.74±1.96</td>
<td>6.86±2.52</td>
<td>8.07±2.15</td>
<td>10.49±2.2</td>
<td>15.91±1.19</td>
<td>21.36±1.80</td>
<td>36.31±3.48</td>
</tr>
<tr>
<td>F6</td>
<td></td>
<td>5.55±0.94</td>
<td>8.00±2.41</td>
<td>17.24±0.7</td>
<td>20.52±2.1</td>
<td>24.75±1.3</td>
<td>34.80±1.63</td>
<td>44.40±1.30</td>
<td>36.31±2.41</td>
</tr>
<tr>
<td>F7</td>
<td></td>
<td>1.39±2.21</td>
<td>4.34±2.08</td>
<td>5.53±2.53</td>
<td>9.07±1.64</td>
<td>12.04±1.8</td>
<td>17.94±2.07</td>
<td>22.69±2.45</td>
<td>36.31±1.31</td>
</tr>
<tr>
<td>F8</td>
<td></td>
<td>1.86±3.32</td>
<td>5.19±2.39</td>
<td>8.26±2.56</td>
<td>12.43±3.6</td>
<td>14.95±2.8</td>
<td>17.45±3.48</td>
<td>21.35±2.73</td>
<td>36.31±1.66</td>
</tr>
</tbody>
</table>

Figure 9: Plot of log cumulative % drug remaining versus time across dialysis membrane for formulation F1, F4 and F6.

Figure 10: Plot of log cumulative % drug remaining versus time across dialysis membrane for formulation F2 and F7.
CONCLUSION

In conclusion we have developed formulation and development of transdermal patches of piroxicam. Transdermal patches increase the patient compliance over conventional dosage form. Transdermal medication delivers a steady infusion of a drug over an extended period of time. An equivalent therapeutic effect can be elicited via transdermal drug input with a lower daily dose of the drug than is necessary, e.g. the drug is given orally. The preformulation study were investigated and had similarity with official standard (I.P. 1996). The wavelength range determined using U.V. Spectrophotometer was found to be 336nm. HPMC, EC, PVP, Ethanol and PEG-400 were used in the formulation of transdermal patches. Eight batches of transdermal patches were prepared using different concentration HPMC, EC and PVP. Evaluation of each formulation was performed and formulation F6 was optimized best, because it had similarity with standard properties of transdermal patches. In-vitro release study provides information that transdermal patch is able to release 99.9% of drug.

REFERENCE


Drug Release Kinetic

The in vitro dissolution data of various formulation was analyzed by fitting the obtained data into various kinetic model to explain the release kinetics. In the present study, it was observed that the in vitro dissolution profile of piroxicam from all the formulations followed zero order kinetics. The n value from drug release experiment for the formulations containing ethyl cellulose polymer alone had n value from 0.383 to 0.427, indicated anomalous non-Fickian type diffusion without swelling. In case of formulations containing HPMC alone or in combination with ethyl cellulose had values from 0.519 to 0.817, indicating anomalous non-Fickian type diffusion with swelling.

![Figure 11: Plot of log cumulative % drug remaining versus time across dialysis membrane for formulation F3, F5 and F8.](image)

| Table 10: Results of kinetic studies of the dissolution data |
|------------------|------------------|------------------|------------------|------------------|
| **Formulation**  | **Zero order**   | **First order**  | **Higuchi’s model** | **Peppas’ model** |
|                  | r                | r                | r                | r                |
| F1               | 0.647            | 0.618            | 0.974            | 0.978            | 0.942            |
| F2               | 0.718            | 0.518            | 0.917            | 0.934            | 0.383            |
| F3               | 0.875            | 0.613            | 0.971            | 0.975            | 0.389            |
| F4               | 0.607            | 0.422            | 0.944            | 0.887            | 0.519            |
| F5               | 0.790            | 0.638            | 0.938            | 0.977            | 0.738            |
| F6               | 0.794            | 0.553            | 0.964            | 0.957            | 0.572            |
| F7               | 0.860            | 0.608            | 0.970            | 0.975            | 0.817            |
| F8               | 0.910            | 0.646            | 0.983            | 0.968            | 0.707            |

CODEN (USA): AJPRHS

ISSN: 2320-4850
